IMRX Immuneering - Class A5.40+0.30 (+5.9%)
IMRX Immuneering - Class A4.39-1.38 (-23.9%)
IMRX Immuneering - Class A6.82+1.60 (+30.7%)
IMRX Immuneering - Class A5.07-3.26 (-39.1%)
After Hours Decliner
IMRX Immuneering - Class A8.33+1.61+24.0%
After Hours:6.46-1.87 (-22.5%)
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Globe NewswireWed, 7-Jan 4:00 PM
After Hours:6.19-2.14 (-25.7%)